Loading
companiesCompany
Sunshine Lake Pharma (HEC)
Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer.
Also called: Sunshine Lake Pharma Co., Ltd.HEC Pharm
Overview
Sunshine Lake Pharma, part of the HEC (Dongyangguang) group in Dongguan, Guangdong, is a Chinese pharmaceutical company with antiviral, metabolic and oncology pipelines. In cancer it is developing clifutinib, a small-molecule FLT3 inhibitor in a phase 3 trial for FLT3-mutated acute myeloid leukaemia, and lerotinib, a small-molecule kinase inhibitor in a phase 3 trial for oesophageal cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the group website.
Headquarters
Dongguan, CN
Scorecard
All companies#356of 1244 companies, score 11
- phase 3 +6
- modalities +2
- registry trials +3
0 approved, 2 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3small molecule
Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.
Similar pages
cancers
fronts
drugs
Phase 3small molecule
Phase 3small molecule (structure undisclosed or not yet in PubChem)